StocksMedium•4 November 2026•
1 min read
FDA Grants Emergency Use Authorization for Merck's Bravecto
Key Facts
1The U.S. FDA issued an emergency use authorization for Merck's Bravecto to treat screwworm infestations in dogs.
The U.S. FDA issued an emergency use authorization for Merck's Bravecto to treat screwworm infestations in dogs. Benzinga reported that the authorization was granted to address the parasitic condition under emergency protocols, specifically issued to Merck's animal health division, Intervet.
Merck (MRK) closed at $144.67 on November 3, 2026, with the stock reaching a day high of $147.62 and a low of $143.47 during the session. This regulatory milestone follows recent economic data showing Atlanta Fed GDPNow growth at 3.3% as of October 31, 2026.